Travere Therapeutics (NASDAQ:TVTX) Stock Gets Price Target Reduction from Guggenheim

Posted by Brenda Bartman on Nov 7th, 2026

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price decreased by Guggenheim from $89.00 to $78.00 in a research report sent to investors on Wednesday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other analysts have also issued reports on the company. Citigroup raised their price target on Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research note on Monday, August 17th. Evercore set a $78.00 price objective on shares of Travere Therapeutics in a research note on Monday, August 10th. TD Cowen increased their price objective on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Friday, September 18th. Eleven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $68.45.

Get Our Latest Analysis on TVTX

Travere Therapeutics Trading Up 1.5%

TVTX stock traded up $0.73 during midday trading on Wednesday, hitting $49.60. The stock had a trading volume of 1,006,200 shares, compared to its average volume of 2,096,064. The company’s 50-day moving average price is $57.40 and its 200 day moving average price is $47.00. The company has a debt-to-equity ratio of 24.58, a current ratio of 4.05 and a quick ratio of 3.99. The firm has a market cap of $4.68 billion, a PE ratio of -38.45 and a beta of 1.11. Travere Therapeutics has a 12-month low of $22.59 and a 12-month high of $68.73.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.49). The business had revenue of $224.56 million for the quarter, compared to analysts’ expectations of $195.29 million. Travere Therapeutics had a negative return on equity of 152.48% and a negative net margin of 18.66%. The company’s revenue for the quarter was up 36.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.28 EPS. On average, equities research analysts predict that Travere Therapeutics will post -0.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Travere Therapeutics news, EVP Peter Heerma sold 172,717 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $63.43, for a total transaction of $10,955,439.31. Following the completion of the sale, the executive vice president owned 117,066 shares of the company’s stock, valued at approximately $7,425,496.38. The trade was a 59.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Cline sold 50,508 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $3,148,668.72. Following the sale, the chief financial officer directly owned 87,508 shares of the company’s stock, valued at approximately $5,455,248.72. This trade represents a 36.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,294,029 shares of company stock worth $79,454,261. Corporate insiders own 4.44% of the company’s stock.

Institutional Trading of Travere Therapeutics

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC increased its position in Travere Therapeutics by 53.4% during the 2nd quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after purchasing an additional 211 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Travere Therapeutics during the third quarter valued at approximately $37,000. Corient Private Wealth LP lifted its position in Travere Therapeutics by 1.4% during the second quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock valued at $2,734,000 after buying an additional 648 shares in the last quarter. Allworth Financial LP grew its stake in Travere Therapeutics by 98.7% during the third quarter. Allworth Financial LP now owns 1,657 shares of the company’s stock worth $94,000 after buying an additional 823 shares during the period. Finally, Swiss National Bank grew its stake in Travere Therapeutics by 0.6% during the first quarter. Swiss National Bank now owns 168,100 shares of the company’s stock worth $4,994,000 after buying an additional 1,000 shares during the period.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

Positive Sentiment: Canaccord Genuity raised its price target to $72 from $70 and maintained a Buy rating, signaling continued confidence in the shares. Article: Travere Therapeutics Stock Gets Price Target Increase from Canaccord Genuity Group
Positive Sentiment: HC Wainwright kept its Buy rating and $67 target while raising its earnings forecasts for 2027–2030, including its 2030 EPS estimate to $6.84 from $5.73. The revisions point to stronger expected longer-term earnings.
Neutral Sentiment: Analyst actions were mixed: Leerink Partners cut its target to $67 from $78 but retained an Outperform rating, while Guggenheim also lowered its target; the report provided no revised figure. Article: Travere Therapeutics Stock Price Target Cut by Guggenheim
Negative Sentiment: Travere’s latest quarterly results missed sharply on earnings: EPS was a loss of $0.55 versus the expected loss of $0.06. Revenue beat estimates at $224.56 million and rose 36.2% year over year, but the earnings shortfall contributed to reports of a post-results share-price gap down. Article: Travere Therapeutics Shares Gap Down After Earnings Miss

Travere Therapeutics Company Profile

(Get Free Report)

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.